氯苯唑酸对转甲状腺素蛋白淀粉样心肌病患者心功能的影响:ATTR-ACT随机临床试验的事后分析
该研究为ATTR-ACT试验的事后探索性分析,纳入436例转甲状腺素蛋白淀粉样心肌病患者,比较氯苯唑酸80mg与安慰剂对30个月内心功能变化的影响。结果显示氯苯唑酸80mg减轻了左室每搏量、整体纵向应变及E/e'的恶化,且约半数患者基线左室射血分数保留。
要点
- 氯苯唑酸80mg较安慰剂减缓左室收缩和舒张功能指标恶化。
- ATTR-CM患者中约一半基线射血分数保留,近一半为轻度降低或降低。
- 心衰患者无论射血分数如何,均应考虑ATTR-CM可能。
核心结论
- 与安慰剂相比,氯苯唑酸80mg在30个月内减缓了ATTR-CM患者左室收缩和舒张功能的下降。
研究设计与样本
- ATTR-ACT试验的探索性事后分析,为多中心、国际、双盲、安慰剂对照3期随机临床试验,共纳入441例患者,其中436例有超声心动图数据。
关键数值与推荐
- 左室射血分数保留定义为≥50%,轻度降低为41%-49%,降低为≤40%。
临床怎么用
- 对于心衰患者,无论左室射血分数如何,均应考虑ATTR-CM的可能诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tafamidis has been shown to improve survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo. However, its effect on cardiac function has not been fully characterized. OBJECTIVE: To examine the effect of tafamidis on cardiac function in patients with ATTR-CM. DESIGN, SETTING, AND PARTICIPANTS: This was an exploratory, post hoc analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), a multicenter, international, double-blind, placebo-controlled phase 3 randomized clinical trial conducted from December 2013 to February 2018. The ATTR-ACT included 48 sites in 13 counties and enrolled patients aged 18 to 90 years with ATTR-CM. Data were analyzed from July 2018 to September 2023. INTERVENTION: Patients were randomized to tafamidis meglumine, 80 mg or 20 mg, or placebo for 30 months. MAIN OUTCOMES AND MEASURES: Patients were categorized based on left ventricular (LV) ejection fraction at enrollment as having heart failure with preserved ejection fraction (≥50%), mildly reduced ejection fraction (41% to 49%), or reduced ejection fraction (≤40%). Changes from baseline to month 30 in LV ejection fraction, LV stroke volume, LV global longitudinal strain, and the ratio of early mitral inflow velocity to septal and lateral early diastolic mitral annular velocity (E/e') were compared in patients receiving tafamidis, 80 mg, vs placebo. RESULTS: A total of 441 patients were randomized in ATTR-ACT, and 436 patients had available echocardiographic data. Of 436 included patients, 393 (90.1%) were male, and the mean (SD) age was 74 (7) years. A total of 220 (50.5%), 119 (27.3%), and 97 (22.2%) had heart failure with preserved, mildly reduced, and reduced LV ejection fraction, respectively. Over 30 months, there was less pronounced worsening in 4 of the echocardiographic measures in patients receiving tafamidis, 80 mg (n = 176), vs placebo (n = 177) (least squares mean difference: LV stroke volume, 7.02 mL; 95% CI, 2.55-11.49; P = .002; LV global longitudinal strain, -1.02%; 95% CI, -1.73 to -0.31; P = .005; septal E/e', -3.11; 95% CI, -5.50 to -0.72; P = .01; lateral E/e', -2.35; 95% CI, -4.01 to -0.69; P = .006). CONCLUSIONS AND RELEVANCE: Compared with placebo, tafamidis, 80 mg, attenuated the decline of LV systolic and diastolic function over 30 months in patients with ATTR-CM. Approximately half of patients had mildly reduced or reduced LV ejection fraction at enrollment, suggesting that ATTR-CM should be considered as a possible diagnosis in patients with heart failure regardless of underlying LV ejection fraction. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01994889.
引用
- Shah SJ, Fine N, Garcia-Pavia P, et al. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 37966817. doi:10.1001/jamacardio.2023.4147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。